NASDAQ:AMAG AMAG Pharmaceuticals (AMAG) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free AMAG Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$13.75▼$13.7550-Day Range$13.69▼$13.7552-Week Range$4.41▼$13.80VolumeN/AAverage Volume950,664 shsMarket Capitalization$477.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get AMAG Pharmaceuticals alerts: Email Address Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About AMAG Pharmaceuticals Stock (NASDAQ:AMAG)AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.Read More Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. AMAG Stock News HeadlinesApril 25, 2024 | finance.yahoo.comHospital Care Collaboration and Licensing Deals, 2016-2024: Benchmark Analysis of Deals Entered Into by the World's Leading Biopharma CompaniesApril 9, 2024 | finanznachrichten.deAMAG Technology Introduces Symmetry Control RoomMay 4, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 8, 2024 | finanznachrichten.deAMAG Technology Announces Company Badge in Google WalletApril 8, 2024 | finance.yahoo.comAMAG Technology Announces Company Badge in Google Wallet(TM)March 4, 2024 | finance.yahoo.comConvergent Therapeutics Appoints Scott Myers as Chairman of its Board of DirectorsFebruary 1, 2024 | uk.finance.yahoo.comGlobal Iron Deficiency Anemia Therapy Market Poised for Growth, Forecasted to Reach $4.6 Billion by 2030January 23, 2024 | finanznachrichten.deArizton Advisory & Intelligence: The Global IV and Oral Iron Drugs Market Sees Explosive Growth, the Market to Reach $16.34 Billion by 2029 - AriztonMay 4, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)January 12, 2024 | msn.comWhy Vera Therapeutics Stock Soared by 22% This WeekJanuary 9, 2024 | finance.yahoo.comAkebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial OfficerJanuary 8, 2024 | markets.businessinsider.comVera Therapeutics Appoints Robert Brenner As CMODecember 5, 2023 | finance.yahoo.comIntravenous (IV) Iron Formulations Market To Reach USD 6.4 Billion By 2032October 15, 2023 | thestreet.comAMAG's Feraheme Closer to ApprovalOctober 4, 2023 | wsj.comAMAG Austria Metall AGJune 22, 2023 | marketwatch.comContrast Agents Market Size, Share, Emerging Trends, Key Growth Drivers, Challenges and Industry Revenue Outlook 2022-2030June 13, 2023 | finance.yahoo.comLandsdowne Labs Names Bryan Laulicht CEOMay 31, 2023 | finanznachrichten.deLandos Biopharma, Inc.: Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.May 30, 2023 | finance.yahoo.comLandos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.May 17, 2023 | marketwatch.comCA 125 Test Market Research | 2023-2030May 17, 2023 | marketwatch.comGlobal Iron Deficiency Anemia Therapy Market Analysis of New Report 2023-2030May 17, 2023 | finance.yahoo.comIntravenous Iron Drugs Global Market Report 2023: Upsurge in Chronic Renal Disease Bolsters DemandMay 11, 2023 | marketwatch.comNanometals Market Research | 2023-2030May 11, 2023 | marketwatch.com2023, Female Sexul Dysfunction Treatment Market | Global Industry Analysis Till 2030May 11, 2023 | marketwatch.comAnemia Treatment Drugs Market Report Help to Grape the Latest Scenario 2023-2030May 10, 2023 | finanznachrichten.deViridian Therapeutics, Inc: Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 9, 2023 | marketwatch.comIntravenous (IV) Iron Drugs Market Top Players, Revenue, Share, Future Trends, Size, Report and Forecast 2028See More Headlines Receive AMAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AMAG Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/11/2020Today5/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:AMAG CUSIP00163U10 CIK792977 Webwww.amagpharma.com Phone617-498-3300FaxN/AEmployees440Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-466,460,000.00 Net Margins-74.93% Pretax MarginN/A Return on Equity-16.92% Return on Assets-5.96% Debt Debt-to-Equity Ratio1.13 Current Ratio1.75 Quick Ratio1.45 Sales & Book Value Annual Sales$327.75 million Price / Sales1.46 Cash FlowN/A Price / Cash FlowN/A Book Value$7.37 per share Price / Book1.87Miscellaneous Outstanding Shares34,725,000Free FloatN/AMarket Cap$477.47 million OptionableOptionable Beta0.89 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. William K. Heiden (Age 60)CEO, Pres & Director Comp: $1.28MMr. Anthony Casciano (Age 43)Exec. VP & COO Comp: $625.19kMr. Joseph D. Vittiglio (Age 48)Exec. VP, Gen. Counsel, Chief Bus. Officer & Corp. Sec. Comp: $672.28kMr. Scott D. Myers M.B.A. (Age 54)Pres, CEO & Director Mr. Brian Piekos (Age 46)Exec. VP & CFO Ms. Linda S. LennoxVP of Investor Relations & Corp. CommunicationsMr. Amit VermaVP of MarketingMs. Kelly SchickSr. VP, Chief HR Officer & Head of Corp. EngagementDr. Laura Williams M.D.M.P.H., Sr. VP of Clinical Devel.Mr. Peter BawinSr. VP & GM of Cord Blood RegistryMore ExecutivesKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXXOMANASDAQ:XOMAVanda PharmaceuticalsNASDAQ:VNDAVerastemNASDAQ:VSTMMerrimack PharmaceuticalsNASDAQ:MACKView All Competitors AMAG Stock Analysis - Frequently Asked Questions How were AMAG Pharmaceuticals' earnings last quarter? AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) posted its quarterly earnings results on Monday, May, 11th. The specialty pharmaceutical company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.27. The specialty pharmaceutical company earned $68.66 million during the quarter, compared to the consensus estimate of $64.95 million. AMAG Pharmaceuticals had a negative net margin of 74.93% and a negative trailing twelve-month return on equity of 16.92%. Read the conference call transcript. What other stocks do shareholders of AMAG Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AMAG Pharmaceuticals investors own include Palatin Technologies (PTN), Bausch Health Companies (BHC), Broadcom (AVGO), Gilead Sciences (GILD), Netflix (NFLX), Energy Transfer (ET), Ford Motor (F), Tesla (TSLA) and NVIDIA (NVDA). This page (NASDAQ:AMAG) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe Gold Grab of the CenturyColonial Metals4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AMAG Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.